The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Characterization of a Preclinical Model Bearing a Parkinson’s Disease–linked Mutation in PLA2G6
Study Rationale: Mutations in the PLA2G6 gene lead to neurodegeneration linked to Parkinson’s disease (PD), but the mechanism is unknown. The gene encodes an enzyme that breaks down the lipid...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Targeting Mitochondrial Complex I in Parkinson’s Disease
Study Rationale: Three of the primary risk factors for Parkinson's disease (PD)—aging, environmental toxins and genetic mutations—all lead to impaired function of mitochondria, structures that...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Evaluating the Role of CK1d Inhibition in Sleep Dysregulation and Alpha-synuclein Pathology in Preclinical Models of Parkinson’s Disease
Study Rationale: Disrupted sleep is an early sign of Parkinson’s disease (PD) that worsens as the disease progresses. Chronic symptoms of PD include alternations in sleep patterns and changes in the...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Brain-specific LRRK Inhibitors for Parkinson’s Disease
Study Rationale: Mutations in LRRK2 are thought to be causative for Parkinson’s disease (PD), but increases in LRRK2 activity have also been observed in non-familial cases of PD. As a result, LRRK2...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Developing a Method to Exclude Individuals with Insignificant Alpha-synuclein Aggregates from Trials of Therapies that Target Alpha-synuclein
Study Rationale: Alpha-synuclein is a protein that forms clumps in the brain in Parkinson’s disease (PD). Although alpha-synuclein aggregation is a common cause of dementia, other proteins are also...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Using the Biopark Cohort to Study Neuronal Synuclein Disease Types
Study Rationale: To study the pathogenic processes underlying Parkinson’s disease (PD), we have recruited a cohort of several hundred people, including those with hereditary PD, those that carry PD...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.